Therapy Detail

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Therapy Name	Tulmimetostat
Synonyms
Therapy Description	Tulmimetostat is a second-generation inhibitor of EZH1 and EZH2, which potentially decreases tumor cell viability and reduces tumor growth (PMID: 38833522).

Filtering

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Filter rows:

Showing 1 to 1 of 1 entries

Drug Name	Trade Name	Synonyms	Drug Classes	Drug Description
Tulmimetostat		CPI0209\|CPI-0209\|CPI 0209	EZH1 inhibitor 5 EZH2 inhibitor 20	Tulmimetostat is a second-generation inhibitor of EZH1 and EZH2, which potentially decreases tumor cell viability and reduces tumor growth (PMID: 38833522).

Showing 1 to 1 of 1 entries

Filter rows:

Filtering

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Filter rows:

Showing 1 to 6 of 6 entries

Molecular Profile	Indication/Tumor Type	Response Type	Therapy Name	Approval Status	Evidence Type	Efficacy Evidence	References
ARID1A inact mut	urinary bladder cancer	sensitive	Tulmimetostat	Preclinical - Pdx	Actionable	In a preclinical study, Tulmimetostat inhibited tumor growth in a bladder cancer patient-derived xenograft (PDX) model harboring a loss of function mutation in ARID1A (PMID: 38833522).	38833522
ARID1A inact mut	endometrial cancer	sensitive	Tulmimetostat	Preclinical - Pdx	Actionable	In a preclinical study, Tulmimetostat inhibited tumor growth in endometrial cancer patient-derived xenograft (PDX) models harboring loss of function mutations in ARID1A (PMID: 38833522).	38833522
ARID1A P549fs ARID1A N756fs	ovarian clear cell carcinoma	sensitive	Tulmimetostat	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Tulmimetostat inhibited viability of an ovarian clear cell carcinoma cell line harboring ARID1A N756fs and P549fs in culture and inhibited tumor growth in a cell line xenograft model (PMID: 38833522).	38833522
ARID1A G1450fs	urinary bladder cancer	sensitive	Tulmimetostat	Preclinical - Cell culture	Actionable	In a preclinical study, Tulmimetostat inhibited viability in 5/6 bladder cancer cell lines harboring ARID1A loss of function mutations including ARID1A G1450fs in culture (PMID: 38833522).	38833522
ARID1A S2256*	urinary bladder cancer	sensitive	Tulmimetostat	Preclinical - Cell culture	Actionable	In a preclinical study, Tulmimetostat inhibited viability in 5/6 bladder cancer cell lines harboring ARID1A loss of function mutations including ARID1A S2256* in culture (PMID: 38833522).	38833522
ARID1A S552*	urinary bladder cancer	sensitive	Tulmimetostat	Preclinical - Cell culture	Actionable	In a preclinical study, Tulmimetostat inhibited viability in 5/6 bladder cancer cell lines harboring ARID1A loss of function mutations including ARID1A S552* in culture (PMID: 38833522).	38833522

Showing 1 to 6 of 6 entries

Filter rows:

Filtering

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Filter rows:

Showing 1 to 2 of 2 entries

Clinical Trial	Phase	Therapies	Title	Recruitment Status	Covered Countries	Other Countries
NCT04104776	Phase Ib/II	Enzalutamide + Tulmimetostat Tulmimetostat	A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas	Recruiting	USA \| POL \| ITA \| GBR \| FRA \| ESP	1
NCT05944562	Phase I	Tulmimetostat	Tulmimetostat (CPI-0209) in Patients With Mycosis Fungoides and Sezary Syndrome	Recruiting	USA	0

Showing 1 to 2 of 2 entries

Filter rows:

Additional content available in CKB BOOST